SEC Form 4 · accession 0001237899-18-000023
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
P Roy Vagelos
Officer — Chairman of the Board · Director
Period of report
Dec 12, 2018
Accepted (ET)
Dec 14, 2018 · 4:49 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 29, 2018 | G | 12,500 | $0.00 | D | 387,449 | D | |
| Common Stock | Nov 13, 2018 | G | 37,209 | $0.00 | D | 350,240 | D | |
| Common Stock | Nov 15, 2018 | G | 19,202 | $0.00 | D | 331,038 | D | |
| Common Stock | Nov 16, 2018 | G | 16,161 | $0.00 | D | 314,877 | D | |
| Common Stock | Dec 12, 2018 | S | 6 | $382.32 | D | 2,304 | I | By 401(k) Plan |
| Common Stock | Oct 4, 2018 | G | 521 | $0.00 | D | 147,413 | I | by CLAT |
| Common Stock | holding | — | — | — | 83,652 | I | by Spouse as Trustee | |
| Common StockF1 | holding | — | — | — | 1,203 | I | by trust for grandch |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $381.40 | Dec 12, 2018 | A | 36,273 | A | — | Dec 12, 2028 | Common Stock | 36,273 | 36,273 | D |
Explanation of responses
- F1By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
- F2The stock option award vests in four equal annual installments, commencing one year after the date of grant.